Encompass Health Co. (NYSE:EHC – Get Rating) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $64.13.
→ Solar Industry at Start of Long Bull Run? (From Investing Trends)
A number of research firms recently commented on EHC. TheStreet raised shares of Encompass Health from a “c+” rating to a “b-” rating in a report on Wednesday, December 21st. StockNews.com started coverage on shares of Encompass Health in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Raymond James boosted their target price on shares of Encompass Health from $65.00 to $72.00 and gave the company a “strong-buy” rating in a report on Friday, October 28th. Finally, Stephens lowered their target price on shares of Encompass Health from $60.00 to $58.00 and set an “overweight” rating on the stock in a report on Friday, October 28th.
In other news, Director Greg D. Carmichael purchased 1,830 shares of Encompass Health stock in a transaction dated Monday, October 31st. The stock was purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the director now directly owns 10,546 shares of the company’s stock, valued at $576,549.82. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.70% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EHC. Wipfli Financial Advisors LLC purchased a new position in Encompass Health in the third quarter worth $25,000. CWM LLC grew its position in Encompass Health by 67.6% in the third quarter. CWM LLC now owns 625 shares of the company’s stock worth $28,000 after acquiring an additional 252 shares in the last quarter. Worth Asset Management LLC purchased a new position in Encompass Health in the first quarter worth $35,000. Eagle Bay Advisors LLC grew its position in Encompass Health by 137.5% in the second quarter. Eagle Bay Advisors LLC now owns 1,019 shares of the company’s stock worth $57,000 after acquiring an additional 590 shares in the last quarter. Finally, SeaCrest Wealth Management LLC purchased a new position in Encompass Health in the second quarter worth $85,000. 96.14% of the stock is currently owned by hedge funds and other institutional investors.
Encompass Health Trading Up 1.5 %
NYSE:EHC opened at $62.25 on Friday. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 1.59. The stock has a market capitalization of $6.21 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 2.57 and a beta of 1.02. The firm’s 50 day moving average is $58.21 and its 200 day moving average is $52.99. Encompass Health has a 12 month low of $44.33 and a 12 month high of $74.61.
Encompass Health (NYSE:EHC – Get Rating) last posted its quarterly earnings results on Wednesday, October 26th. The company reported $0.67 EPS for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.06 billion. Encompass Health had a return on equity of 15.59% and a net margin of 5.39%. Sell-side analysts expect that Encompass Health will post 2.79 earnings per share for the current year.
Encompass Health Company Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.